| Literature DB >> 28544850 |
Corinne Cayatte1, Alexander Marin2, Gaurav Manohar Rajani1, Kirsten Schneider-Ohrum1, Angie Snell Bennett1, Jason D Marshall1, Alexander K Andrianov2.
Abstract
PCPP, a well-defined polyphosphazene macromolecule, has been studied as an immunoadjuvant for a soluble form of the postfusion glycoprotein of respiratory syncytial virus (RSV sF), which is an attractive vaccine candidate for inducing RSV-specific immunity in mice and humans. We demonstrate that RSV sF-PCPP formulations induce high neutralization titers to RSV comparable to alum formulations even at a low PCPP dose and protect animals against viral challenge both in the lung and in the upper respiratory tract. PCPP formulations were also characterized by Th1-biased responses, compared to Th2-biased responses that are more typical for RSV sF alone or RSV sF-alum formulations, suggesting an inherent immunostimulating activity of the polyphosphazene adjuvant. We defined these immunologically active RSV sF-PCPP formulations as self-assembled water-soluble protein-polymer complexes with distinct physicochemical parameters. The secondary structure and antigenicity of the protein in the complex were fully preserved during the spontaneous aqueous self-assembly process. These findings further advance the concept of polyphosphazene immunoadjuvants as unique dual-functionality adjuvants integrating delivery and immunostimulating modalities in one water-soluble molecule.Entities:
Keywords: complexation; immunoadjuvants; polyphosphazenes; respiratory syncytial virus; self-assembly; vaccine delivery; vaccines
Mesh:
Substances:
Year: 2017 PMID: 28544850 DOI: 10.1021/acs.molpharmaceut.7b00118
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939